A brain reward circuit inhibited by next-generation weight-loss drugs in mice
Next‑generation weight‑loss drugs based on glucagon‑like peptide‑1 receptor agonists (GLP‑1RAs) inhibit a specific brain reward circuit that controls “hedonic feeding”—eating for pleasure rather than hunger—in mice.
Which brain circuit is affected?
The key pathway involves GLP‑1 receptors on a distinct population of neurons in the central amygdala, a region linked to emotion and motivation. Activation of these amygdalar neurons suppresses dopamine release into the nucleus accumbens, a core hub of the brain’s reward system. This reduces the rewarding value of palatable foods without completely blocking normal, hunger‑driven eating.
How do the drugs engage this circuit?
Oral small‑molecule GLP‑1RAs (such as danuglipron and orforglipron) penetrate deeper into the brain than older injectable GLP‑1 drugs and bind to GLP‑1 receptors in the central amygdala. Stimulating these amygdalar neurons curtails hedonic feeding, whereas selectively deleting the GLP‑1 receptor in this population blunts the drug’s ability to suppress reward‑driven food intake.
Why this matters beyond weight loss
Because this circuit modulates dopamine signaling in reward‑related pathways, the findings suggest these drugs could also be explored for conditions involving dysregulated reward processing, such as substance‑use disorders or binge‑eating behavior. However, the same mechanism raises questions about potential broader effects on motivation and pleasure, which are still being studied in animal models.
